The Royal Society announced today that the Gurdon Institute's Andrea Brand is one of six world-class scientists to whom they have awarded prestigious Research Professorships
Targeting epigenetic regulators in combination with DNA-damaging agents may offer new selective anti-cancer strategy
22.08.16 Simons lab reveal that imbalanced cell fate, rather than faster cell division, drives cancer development in oesophagus
Publishing in Nature Cell Biology with colleagues from the Sanger Institute, the Simons lab show that subtle changes in cell fate behaviour underlie tumour development
11.07.16 Molecular duo of Patronin and Shot are crucial for polarising microtubules, find St Johnston lab
A new protein complex, Patronin and Shot, is found to support the organisation of microtubules that lead to cell polarisation
07.07.16 Gurdon Institute scientists reveal ultra-high resolution 3D imaging of "virtually any subcellular structure"
The culmination of a decade's research on high-resolution fluorescence imaging techniques, resulting in a dramatically increased imaging depth combined with nanoscale resolution, is presented in new Cell paper
In a new Nature paper, Ben Simons and colleagues combine mathematical modelling with the study of cancer biology, proving that basal cell carcinomas arise specifically from stem cells
Jackson group postdoc Christine Schmidt's new paper in ACS Nano shows how cancer cells behave in see-through nanotubes designed to mimic blood capillaries
28.06.16 Storm Therapeutics, the latest spinout from the Gurdon Institute, raises investment of £12 M
Tony Kouzarides' and Eric Miska's spinout from the Gurdon Institute seeks to find new cancer therapeutic targets among RNA-modifying enzymes
Ben Simons and Philip Greulich show that a model in which stem cells exhibit ‘dynamic heterogeneity’ can robustly explain patterns of self-renewal and differentiation, contributing to our understanding of tissue maintenance.
The Kouzarides lab is working with lab alumnus Mark Dawson in Australia to identify therapeutic targets in the aggressive disease Mixed-Lineage Leukaemia. They report that DOT1L works with known target BRD4 to regulate transcription of key genes.
09.06.16 Simons lab demonstrate power of statistical analysis to resolve multipotency in lineage labelling
In their Genes & Development paper, Ben Simons' group apply statistical analysis to quantify lineage tracing, and show that it is possible to resolve whether stem cells in developing tissues are multipotent.
Live imaging in this Development paper by Dan Bergstralh et al. reveals fine details of dividing cells in the Drosophila wing disc to show that orientation of mitotic spindle does not require the protein Pins.
Gurdon Institute group leader Rick Livesey announces investment from the Dementia Discovery Fund into his new spinout company Gen2 Neuroscience Ltd, which aims to develop disease-modifying drugs for dementia.
Senior Research Associate Julia Tischler describes her first entrepreneurial foray, stimulated by the Cambridge Postdoc Enterprise Competition
The Gurdon Institute's Steve Jackson, Quick Professor of Biology at the University of Cambridge and the Institute's head of Cancer Research UK Laboratories, has won the 2016 Heineken Prize for Medicine.
25.04.16 Piddini lab find that cells compete by squeezing each other to death, offering possible clue to cancer tactic
Eugenia Piddini's group at the Gurdon Institute publishes a study showing that fitter cells squeeze neighbouring cells to death, making room in which to divide and expand. The paper, published in Nature Communications, may provide a clue to how cancer cells invade tissues.
Meri Huch's lab is partner to an EU project, LSFM4LIFE, that aims to develop a therapy for Type 1 diabetes using human pancreatic organoids grown from stem cells
04.04.16 Rawlins lab identify an active signalling mechanism that maintains quiescence in the airway epithelium
New paper in Developmental Cell from the Rawlins lab shows that active signalling via FGFR1 is required to maintain steady-state cell turnover in airway epithelium
A new paper from the Gurdon lab published in Genome Research shows that sperm DNA carries epigenetic marks that influence gene transcription in the embryo
The Livesey lab publish new results on modelling cortical development in vitro in 2D and 3D to explore mechanisms that control final size of the cortex in primates
Pharmaceutical companies and academics gathered over dinner at Jesus College to launch the Milner Therapeutics Institute and Consortium
Golnar Kolahgar from the Piddini lab comments in The Conversation on recent research suggesting that stem cells 'know' their sexual identity
04.02.16 Piddini lab find that stopping tumour cells from killing host tissues could offer new therapeutic approach
A new paper from the Gurdon Institute's Piddini lab suggests that tumours can be prevented from growing if surrounding cells are protected from dying. This offers a potential new focus for fighting cancer by keeping host cells healthy as opposed to targeting the cancer cells to die.
Research by a worldwide team of scientists (including the Gurdon Institute's Azim Surani) has uncovered a regulatory, epigenetic switch that causes individuals with identical genetics to be either lean or obese.
In a Letter to Nature, the Surani lab show that the transcription factor NANOG can act alone to induce primordial germ cells from mouse epiblast-like cells in culture
The prestigious King Faisal International Prize for Science has been won jointly by the Gurdon Institute's Steve Jackson and Harvard Medical School's Vamsi Krishna Mootha
A paper authored by the Gurdon lab's Magda Koziol in Nature Structural and Molecular Biology suggests that DNA modifications are more diverse than previously thought.
Milan Malinsky from the Miska lab is part of research team finding evidence for sympatric speciation in cichlid fish in Africa's Lake Massoko; published in Science, 18 December 2015 issue.
Azim Surani writes for The Conversation on whether germline research is sufficiently advanced to be combined with new gene editing technology
NICE has approved olaparib for use by the NHS for certain ovarian cancer patients, bringing the drug to around 400 women per year in England and Wales